Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolonging spray.
Popular Articles

Warning On Untreated Bitter Lupins After Two Women Become Ill, Australia
Consumers should be warned about the dangers of eating untreated bitter lupin beans after two people who consumed products containing the beans became ill with anticholinergic syndrome, according to an article in the Medical Journal of Australia.
generic viagra
Important Modulator Of Immune Cell Entry Into The Brain Discovered
Researchers in Berlin, Germany have ameliorated inflammation of the brain in mice caused by immune cells.
Zubni implantati
News of the day
Screening Of First-Degree Relatives Of Patients With Bicuspid Aortic Valve Recommended
Bicuspid Aortic Valve (BAV), a condition in which patients" aortic valves have just two leaflets instead of the normal three, is the most common cardiac anomaly, affecting up to two percent of the general population. The defect can result in calcification deposits on the heart valve, leakage of the valve and may results in a feeling of tightness in the chest as well as shortness of breath. The condition is easily diagnosed; often physicians can hear a "click" or a murmur when they listen to a BAV patient"s heart with a stethoscope.
Mental Health

Learning More About The Placebo Effect

In this trial, a sample of alcohol-dependent patients received naltrexone, acamprosate or placebo for 12 weeks. While there were no differences in outcomes between treatment groups, those who believed they had been taking active medication consumed fewer alcoholic drinks and reported less alcohol dependence and cravings. That is, irrespective of actual treatment, perceived medication allocation predicted health outcomes. Double-blind placebo-controlled trials are intended to control for the impact of expectancy on outcomes. Whether they always achieve this is, however, questionable. Reanalysis of a clinical trial of naltrexone and acamprosate for alcohol dependence investigated this issue further. In this trial, 169 alcohol-dependent patients received naltrexone, acamprosate or placebo for 12 weeks. In addition to being assessed on various indices of alcohol dependence, they were asked whether they believed they received active medication or placebo. While there were no differences in outcomes between treatment groups, those who believed they had been taking active medication consumed fewer alcoholic drinks and reported less alcohol dependence and cravings. That is, irrespective of actual treatment, perceived medication allocation predicted health outcomes. These results highlight the differences between treatment administration in clinical trials and standard medical practice, a discrepancy that may sometimes decrease the validity of these types of trials. Psychotherapy and Psychosomatics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009